Overview

SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.

For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov

Our Product Pipeline

Indication
Therapeutic Candidate

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Acute NIHL
Mild to Moderate

SPI-1005

(Phase 2)

60%

Click for Status

Oral SPI-1005 reduced the severity and duration of NIHL.  Link: Clinicaltrials.gov

Meniere’s Disease
SPI-1005

(Phase 2)

50%

Click for Status

Multicenter Ph1b enrollment initiated at end of Q4 2015.  Link: Clinicaltrials.gov

Chemotherapy-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

Pre-clinical results demonstrated significant ability of SPI-3005 to reduce the hearing loss induced by the platinum-based chemotherapeutics.  Link: Clinicaltrials.gov

Aminoglycoside-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

Multicenter Ph1/2 to initiate enrollment Q2 2017.
Link: Clinicaltrials.gov

Severe to Profoundly
Impaired

SPI-5557

(Phase 1)

20%

Click for Status

Anticipate IND filing in Q4 2018

Our Product Pipeline